#Ireland #Dublin #Cardiac Care #LUMA Vision #VERAFEYE

LUMA Vision Expands Clinical Applications with VERAFEYE™

LUMA Vision, a pioneering company in the field of cardiac imaging and navigation, has recently made significant strides in its clinical initiatives by enrolling the first patients in two key European studies utilizing its flagship product, the VERAFEYE™ platform. This is a crucial step in enhancing the efficiency and accuracy of catheter ablation procedures. The studies are taking place at two prominent hospitals: Na Homolce Hospital in Prague, headed by Dr. Vivek Reddy and Dr. Petr Neuzil, and KBC University Hospital in Split, where Dr. Ante Anic and Dr. Anish Amin are leading the effort.

The VERAFEYE™ platform is designed to facilitate catheter ablation procedures through advanced 4D imaging, which allows clinicians to visualize the heart in unprecedented detail. This system employs both live intra-procedural imaging and high-fidelity digital anatomical models, creating a seamless workflow for ablation guidance. The current studies have demonstrated the versatility of the VERAFEYE™ platform as it effectively supports multiple ablation technologies, including Pulsed Field Ablation (PFA) systems, solidifying its standing as a pivotal tool in electrophysiology.

During this development phase, the latest version of the VERAFEYE™ platform has already been submitted for a 510(k) approval, marking the beginning of the regulatory process necessary for commercial launch. This submission is anticipated to set the stage for an enhanced feature set that aims to improve procedural accuracy significantly in cardiac electrophysiology procedures set to begin in 2026.

The significance of this expansion was highlighted during a joint visit from prominent health officials, including Judith Gerlach, Bavaria’s Minister of Health, and Jennifer Carroll MacNeill, Ireland’s Minister of Health. Their visit not only underscored the collaborative efforts between Irish and Bavarian teams but also emphasized the profound impact of European innovation in the realm of cardiac healthcare. Minister MacNeill praised the capabilities of the VERAFEYE™ platform, stating, “What you are building here with the VERAFEYE™ platform is genuinely a world-first technology,” reinforcing the innovative spirit that fuels the growth of the MedTech sector in Europe.

As LUMA Vision prepares for its product launch, the company is poised to expand its reach in key global markets. The real-time imaging and navigation capabilities of the VERAFEYE™ platform enable physicians to leverage their preferred ablation tools, enhancing procedural speed, efficiency, and accuracy. Moreover, LUMA Vision is eyeing future applications that extend beyond ablation, potentially encompassing structural heart interventions, such as left atrial appendage closure and valve placements.

In summary, the advancements made by LUMA Vision signify not only a milestone in cardiac care technology but also reflect the collaborative effort that drives innovation in healthcare systems across Europe. The VERAFEYE™ platform sets a new standard in the cardiac care landscape, promising improved patient outcomes and a transformative approach to heart-related medical procedures. It stands as an exemplary case of how collaborative innovation can lead to breakthrough technologies that advance medical practice and enhance the overall quality of care.

For more information on LUMA Vision and its pioneering technologies, visit LUMA Vision Official Website.